TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3202206
Drug: Metoprolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.15 mg/kg)
Study: 11485845
Drug: Topical delta-aminolaevulinic
Normalized name: Delta Tritex Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical delta-aminolaevulinic acid (ALA) applied under an occlusive dressing for 5 hours on 64 warts.
Study: 30333337
Drug: Chloride liberal
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloride liberal intravenous fluids (IVFs) including hydroxyethyl starch (130/0.4) in 0.9% normal saline (Voluven), 0.9% normal saline, and Ringer's lactate
Study: 30333337
Drug: Chloride restricted
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloride restricted intravenous fluids (IVFs) including hydroxyethyl starch (130/0.4) in balanced colloid solution (Volulyte) and balanced salt crystalloid solution (PlasmaLyte A)
Study: 20148732
Drug: Endoscopic flushes
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic flushes of 20-ml aliquots of water containing Gascon, with or without Pronase
Study: 20148732
Drug: Endoscopic flushes
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic flushes of 20-ml aliquots of water
Study: 11666127
Drug: TTFCA (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFCA (total triterpenic fraction of Centella asiatica) at a dose of 60 mg thrice daily for 12 months
Study: 9699198
Drug: Tibolone, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone, 2.5 mg/day
Study: 9699198
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE), 0.625 mg/day plus medroxyprogesterone acetate (MPA), 5 mg/day
Study: 7989632
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate syrup (30 mg/Kg) and diazepam solution (0.2 mg/Kg)
Study: 7989632
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate syrup (30 mg/Kg) and diphenhydramine HCl (1.5 mg/Kg)
Study: 4537850
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution as the sole intravenous fluid
Study: 4537850
Drug: Three different
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different intravenous solutions to meet all fluid and electrolyte requirements
Study: 31067371
Drug: Progesterone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (400 mg vaginal suppositories twice daily)
Study: 31067371
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching vaginal suppositories)
Study: 23662176
Drug: Inhaled epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epoprostenol (iPGI2) at 50 ng/kg/min
Study: 23662176
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) in HFpEF patients
Study: 23662176
Drug: Inhaled epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epoprostenol (iPGI2) in HFpEF patients
Study: 23662176
Drug: Inhaled epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled epoprostenol (iPGI2)
Study: 23662176
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iNO and iPGI2
Study: 21496284
Drug: Anthracycline-containing chemotherapy
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline-containing chemotherapy (FE(100)C)
Study: 21496284
Drug: Biological risk
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological risk assessment using uPA/PAI-1
Study: 11104313
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment alone
Study: 11104313
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Medication + Psychosocial treatment)
Study: 9195505
Drug: CAMPATH-1H (C1H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH-1H (C1H) 0.5 mg subcutaneously twice per week
Study: 9195505
Drug: CAMPATH-1H (C1H)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH-1H (C1H) 1.0 mg subcutaneously twice per week
Study: 30371745
Drug: Proposed cumulative
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed cumulative incidence regression models for dynamic treatment regimens (DTRs)
Study: 26709136
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and Sitagliptin (GS)
Study: 15811208
Drug: Daily ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ibandronate (2.5 mg)
Study: 15811208
Drug: Intermittent ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent ibandronate (20 mg every other day for 12 doses every 3 months)
Study: 2252195
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion of ketamine, midazolam, and alfentanil with inhalation of isoflurane in oxygen-enriched air
Study: 6997513
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard surgical therapy)
Study: 19835754
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement with socket grafting followed by provisionalization after 4 months
Study: 17360317
Drug: Controlling for
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlling for age, gender, maximum grade of acute GVHD, and treatment arm
Study: 3311138
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for IGT
Study: 2619026
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride (Difflam) spray
Study: 25214516
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study treatment (Control)
Study: 23392966
Drug: Apatite-coated magnetite
Normalized name: magnesite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatite-coated magnetite nanoparticles, injected intravenously or intraperitoneally at doses ranging from 100 to 2,500 mg/Kg.
Study: 19280324
Drug: CRA13 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRA13 administered in fed state
Study: 19280324
Drug: CRA13 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRA13 administered in fasted state
Study: 15636272
Drug: Triazolam (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (one weight-based dose administered 60 minutes prior to treatment)
Study: 15636272
Drug: Triazolam with
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam with supplemental dosage (half the initial dose)
Study: 8501567
Drug: High-titer Edmonston-Zagreb
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer Edmonston-Zagreb (EZ) measles vaccine
Study: 8501567
Drug: Inactivated poliomyelitis
Normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliomyelitis vaccine and standard Schwarz vaccine
Study: 30202998
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) alone or in combination with vitamin E
Study: 30202998
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CoQ10 and Vitamin E
Study: 28566022
Drug: Recovery-Oriented Cognitive
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery-Oriented Cognitive Therapy (CT-R)
Study: 23438670
Drug: Gefitinib 500mg
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 500mg oral daily until progression or severe toxicity
Study: 18469236
Drug: 250 mg/d
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/d EPA + DHA esterified to phospholipid (PL-n-3) (300 mg/d phosphatidylserine)
Study: 10337210
Drug: French cassoulet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: French cassoulet (CASS) 22.5 g/kg
Study: 10337210
Drug: International sauerkraut
Approvals — FDA: no, EMA: no, PMDA: no
Description: International sauerkraut (CHOU) 22.5 g/kg
Study: 1770067
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity maintained (G)
Study: 7104136
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with enflurane
Study: 25164450
Drug: Glucose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose group (acetated Ringer solution with 1.5% glucose)
Study: 25164450
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (acetated Ringer solution without glucose)
Study: 16279144
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects estimated within each trial assuming a common treatment effect across trials.
Study: 16279144
Drug: Subgrouping patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgrouping patients to investigate covariate-treatment interactions.
Study: 9788003
Drug: Disulfiram 500
Normalized name: disulfiram 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram 500 mg/day
Study: 9788003
Drug: Cocaine 1
Normalized name: cocaine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 1 mg/kg
Study: 9788003
Drug: Cocaine 2
Normalized name: cocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 2 mg/kg
Study: 9788003
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for cocaine administration
Study: 2198928
Drug: Cyclosporin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (10 mg/kg/day)
Study: 832447
Drug: Tetrahydrocannabinol (THC)
Normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydrocannabinol (THC) 0.022 mg/kg
Study: 832447
Drug: Tetrahydrocannabinol (THC)
Normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydrocannabinol (THC) 0.044 mg/kg
Study: 832447
Drug: Diazepam 0.157
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.157 mg/kg
Study: 27712113
Drug: Palonosetron IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron IV (0.75 mg)
Study: 27712113
Drug: Palonosetron IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron IV (0.75 mg) and hydroxyzine PO (100 mg)
Study: 26027624
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi Chuan (TCC) cardiac rehabilitation program, 3 weekly sessions for 12 weeks.
Study: 26027624
Drug: Full-body stretching
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-body stretching exercises (control group), 3 weekly sessions for 12 weeks.
Study: 15301901
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium administration
Study: 15301901
Drug: Magnesium administration
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium administration to replenish low serum magnesium concentrations
Study: 15301901
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate for treatment of torsade de pointes
Study: 11702324
Drug: Hydromorphone 283
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 283 micrograms (low dose, LD)
Study: 11702324
Drug: Hydromorphone 566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 566 micrograms (high dose, HD)
Study: 11702324
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydromorphone 283 micrograms and metamizole 50 mg (low dose hydromorphone + metamizole, LM)
Study: 2218190
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of therapies with independent activity
Study: 2218190
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of therapy to patients in a disease-free (remission) state
Study: 75392
Drug: Flufenamic acid
Normalized name: Flufenamic acid
DrugBank: Flufenamic acid (DB02266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flufenamic acid (200 mg three times a day)
Study: 10379482
Drug: Interferon-alfa (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alfa (6 MU t.i.w.) plus ribavirin (1000 mg/daily)
Study: 7675230
Drug: Tegretol-XR 200-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegretol-XR 200-mg tablets every 12 hours
Study: 7675230
Drug: Tegretol 200-mg
Normalized name: carbamazepine 200 MG [Tegretol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegretol 200-mg tablets three or four times daily
Study: 7222869
Drug: Intracervically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracervically applied Prostaglandin F2 alpha Gel
Study: 30730438
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy in patients with intracranial pressure monitoring
Study: 27334444
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (treatment as usual + online psychoeducation about depression)
Study: 17823418
Drug: Twice-weekly strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly strength training for 2 years
Study: 8173852
Drug: 24 h
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 h bed rest following intra-articular steroid injection
Study: 8173852
Drug: Routine outpatient
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine outpatient injections (no rest)
Study: 24018781
Drug: Olmesartan/amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/amlodipine combination 20/5 mg
Study: 20957980
Drug: Ipilimumab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (0.3, 3, or 10 mg/kg)
Study: 20957980
Drug: Ipilimumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (all doses)
Study: 1556836
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of BCG Tokyo 172 strain (80 mg in 40 ml saline, once a week for 8 weeks)
Study: 1556836
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with BCG (40 mg in 40 ml saline, monthly for 12 months)
Study: 28940961
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of metformin (MF+)
Study: 28940961
Drug: Withholding metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding metformin (MF-)
Study: 28053789
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream applied around participants' ankle during locomotor training (Pain group)
Study: 24615429
Drug: High-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega-3 ethyl esters (n-3 PUFA), 2-4 g daily for 12 weeks
Study: 20651615
Drug: Docetaxel monotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel monotherapy (60 mg/m, day 1, q3 weeks)
Study: 20651615
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of docetaxel (40 mg/m, day 1, q3 weeks) and S-1 (80 mg/m, days 1-15)
Study: 20651615
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of docetaxel and S-1
Study: 17560879
Drug: Ezetimibe/Simvastatin (10/10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin (10/10, 10/20, 10/40, or 10/80 mg)
Study: 17560879
Drug: Simvastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10, 20, 40, or 80 mg)
Study: 16018379
Drug: Laxomucil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxomucil (2 sachets, 3.26 g plantago ovata, twice daily for 20 days)
Study: 2914474
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen therapy at 2 L/min
Study: 2914474
Drug: Nasal air
Normalized name: nasal airflow strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal air therapy
Study: 30317291
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous dexamethasone
Study: 30317291
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg dexamethasone infiltrated into the peritonsillar regions
Study: 30317291
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 0.5% bupivacaine infiltration
Study: 18432173
Drug: Rotational atherectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotational atherectomy followed by drug-eluting stent implantation (Rota-DES)
Study: 18432173
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent implantation alone (DES)
Study: 16150034
Drug: Computer-based learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based learning (CBL) programme covering cardiovascular drug therapy (n = 70)
Study: 12829911
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) monotherapy
Study: 12829911
Drug: Azathioprine +
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine + prednisolone dual therapy
Study: 10827214
Drug: 415 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 415 microg folate/d (as diet plus FA or a combination of FA and OJ)
Study: 6191495
Drug: Conventional anti-acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-acne medications (other than salicylic acid and tretinoin)
Study: 28575208
Drug: 12 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weekly doses of directly observed isoniazid and rifapentine (3HP)
Study: 26638010
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every-2-weeks (Q2W)
Study: 26638010
Drug: Double-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose rosuvastatin
Study: 25129515
Drug: 15% DEET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% DEET topical repellent
Study: 19234056
Drug: Energy reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy reduction diet (reduce daily intake by 500 kcal and limit energy from fat to <or=25%)
Study: 12790845
Drug: Single combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single combined preoperative dose of gentamicin (160 mg) and metronidazole (500 mg)
Study: 12790845
Drug: Postoperative standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative standard scheme of antibiotics over 7 days
Study: 12790845
Drug: Single combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single combined preoperative dose of gentamicin and metronidazole
Study: 8836419
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (XRT) as adjuvant after chemotherapy
Study: 8836419
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (XRT) for partial responders (PRs) after chemotherapy
Study: 8836419
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (XRT) as salvage treatment for asymptomatic limited nodal relapse
Study: 8836419
Drug: XRT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: XRT in high-dose therapy programs
Study: 1734801
Drug: Intramuscular famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular famotidine 20 mg (group F2)
Study: 1734801
Drug: Intramuscular famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular famotidine 20 mg (group F3)
Study: 1734801
Drug: Intramuscular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular saline (placebo, group P2)
Study: 1734801
Drug: Intramuscular famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular famotidine 20 mg (group F1)
Study: 1734801
Drug: Intramuscular saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular saline (placebo, group P3)
Study: 6539662
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg Gemeprost vaginal suppository
Study: 28341108
Drug: Nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 every 3 weeks)